Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer

Aleksandra M Ochnik1, Robert C Baxter2

  • 1Kolling Institute of Medical ResearchUniversity of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia aleksandra.ochnik@sydney.edu.au.

Endocrine-Related Cancer
|October 14, 2016
PubMed

Insights

Targeting insulin-like growth factor 1 receptor (IGF1R) in breast cancer shows promise but faces challenges due to complex signaling. New therapeutic strategies are needed to effectively target IGF1R activity and its downstream pathways in tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Insulin-like growth factor 1 receptor (IGF1R) signaling is crucial in breast cancer development and progression.
  • Despite extensive research, clinical translation of IGF1R-targeted therapies has yielded limited success.
  • The complex interplay of growth factor receptor signaling networks complicates isolated targeting strategies.

Purpose of the Study:

  • To review current literature and clinical trials on IGF-1 signaling in breast cancer.
  • To explore novel therapeutic approaches for IGF1R-directed breast cancer treatment.
  • To address challenges in targeting IGF1R and its downstream pathways.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of IGF1R expression and activity in breast cancer.
  • Discussion of complex signaling networks involving tyrosine kinase receptors.
  • Exploration of new therapeutic design strategies.

Main Results:

  • IGF1R plays a significant biological role in breast cancer.
  • Clinical efficacy of targeting IGF1R alone has been limited.
  • Cancer cell signaling is complex, involving cross-talk between multiple receptors.
  • Isolated study of IGF1R has inherent limitations for therapeutic development.

Conclusions:

  • Effective breast cancer therapy requires understanding the complexity of IGF1R signaling.
  • Novel therapeutic strategies should consider targeting IGF1R activity and downstream pathways.
  • Further research is needed to overcome challenges in clinical translation of IGF1R-targeted therapies.
Keywords:
breast cancerinsulin-like growth factor receptortargeted therapies and sphingosine kinase

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.3K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.5K